Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET

Company Participants

Neda Safarzadeh - IR

Joseph Payne - President & CEO

Andrew Sassine - CFO

Padmanabh Chivukula - Chief Scientific Officer & Chief Operating Officer

Conference Call Participants

Seamus Fernandez - Guggenheim

Yanan Zhu - Wells Fargo Securities

Ashiq Mubarack - Citi

Pete Stavropoulos - Cantor Fitzgerald

Operator

Greetings, and welcome to the Arcturus Therapeutics Fourth Quarter 2022 Financial Update and Pipeline Progress Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing. Thank you. You may begin.

Neda Safarzadeh

Thank you, operator. Good afternoon, and welcome to Arcturus Therapeutics’ fourth quarter 2022 financial update and pipeline progress call. Today's call will be led by Joseph Payne, our President and CEO; and Andy Sassine, our CFO. Dr. Pad Chivukula, our CSO and COO, will join in for the Q&A session as well.

Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance and achievements to differ materially from those expressed or implied by the statements.

Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our Form 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements to reflect future information, events or circumstances.

And with that, I'll now turn the call over to Joe.

Joseph Payne

Hey. Thank you, Neda, and good afternoon to all. Thank you for joining us for today's call. The recent period has been characterized by substantial operational and pipeline progress here at Arcturus. We will be highlighting four areas on today's update call.

First, we closed our strategic vaccine collaboration agreement with CSL Seqirus at the end of last year. We have received the $200 million upfront payment and invoiced $90 million in additional milestones. Demonstrating the positive progress that the companies have made on our partnered COVID and seasonal flu vaccine programs.